England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...
At Multiple Sclerosis News Today, stories about the keto diet, myelin repair, and vitamin D topped this year's most-read list ...
The team, consisting of researchers from University College London (UCL) and Queen Square Analytics, analysed 634 patients ...
As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...
Patients included in a new study were grouped by initiation of high-efficacy or moderate-efficacy disease-modifying therapy (DMT). The most common reasons for DMT de-escalation were positivity for JC ...
"The observed differential effects of high-efficacy disease-modifying agents across sexes underscore the importance of sex-specific considerations in making treatment decisions to personalize care in ...
Thousands of people in England with a type of multiple sclerosis (MS) are set to benefit from a new treatment on the NHS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback